Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients with relapsed or refractory multiple myeloma: Subgroup analysis of POLLUX and CASTOR (https://www.myeloma.org/videos/safety-efficacy-daratumumab-based-regimens-elderly-75-y-patients-relapsed-or-refractory)
Dr. Saad Z. Usmani Discusses the POLLUX and CASTOR Trials
Background: Daratumumab (D) plus lenalidomide and dexamethasone (Rd; POLLUX) or with bortezomib and dexamethasone (Vd; CASTOR) demonstrated prolonged progression-free survival (PFS) and tolerability compared with Rd and Vd alone, respectively, in relapsed/refractory multiple myeloma (RRMM) patients. We examined the safety and efficacy profiles of DRd and DVd in elderly (≥75 y) patients from these phase 3 studies.
Conclusions: The safety and efficacy profiles in elderly pts were generally comparable with the overall population in each study.
Author(s): Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja C. Weisel, Michele Cavo, Jacob Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Zafar Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jordan Mark Schecter, Kaida Wu, Xiang Qin, David Soong, Meletios A. Dimopoulos
Clinical trial information: NCT02136134 (http://clinicaltrials.gov/show/NCT02136134%20and%20NCT02076009) and NCT02076009 (http://clinicaltrials.gov/show/NCT02136134%20and%20NCT02076009)
ABOUT SAAD USMANI, MD
Dr. Saad Usmani is Chief of Plasma Cell Disorders and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute Hematologic Oncology and Blood Disorders and Carolinas HealthCare System.